Semper Paratus Acquisition in a regulatory filing said shareholders approved extending the SPAC’s deadline in monthly increments to September 2024. In return, the SPAC has agreed to deposit into trust the lesser of $22,500 or 1.5 cents a share for each month required.
Redemptions of 880,873 shares at $11.02 per share removed approximately $9.7 million from the SPAC’s trrust, leaving $16.5 million.
Semper Paratus has a deal in hand with Tevogen.
The target is a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in virology, oncology, and neurology.
Announced in June, the deal has a pro forma equity value of approximately $1.2 billion.
Sempter Paratus raised $345 million in a November 2021 IPO. The SPAC in May sold its sponsor equity to SSVK Associates. Read more.
